Cardiovascular Systems - CSII Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.00
  • Forecasted Upside: 48.81 %
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$13.44
▲ +0.01 (0.07%)

This chart shows the closing price for CSII by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cardiovascular Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CSII and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CSII

Analyst Price Target is $20.00
▲ +48.81% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cardiovascular Systems in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 48.81% upside from the last price of $13.44.

This chart shows the closing price for CSII for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Cardiovascular Systems. This rating has held steady since February 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/14/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2022Bank of AmericaInitiated CoverageUnderperform ➝ UnderperformLow
2/4/2022SVB LeerinkLower TargetOutperform$25.00 ➝ $20.00High
11/17/2021Needham & Company LLCDowngradeBuy ➝ HoldMedium
11/10/2021OppenheimerLower TargetOutperform$48.00 ➝ $40.00High
11/10/2021GuggenheimDowngradeBuy ➝ NeutralHigh
11/10/2021SVB LeerinkLower TargetOutperform$45.00 ➝ $40.00High
9/26/2021SVB LeerinkReiterated RatingBuyLow
9/23/2021Needham & Company LLCLower TargetBuy$50.00 ➝ $49.00Low
7/23/2021SVB LeerinkSet TargetBuy$38.75Low
7/16/2021Northland SecuritiesReiterated RatingBuy$45.00Low
5/24/2021BarclaysInitiated CoverageEqual Weight$43.00Medium
3/17/2021OppenheimerReiterated RatingBuy$48.00High
2/15/2021AegisReiterated RatingBuyMedium
2/4/2021Needham & Company LLCBoost TargetBuy$47.00 ➝ $50.00High
12/16/2020Northland SecuritiesBoost TargetOutperform$40.00 ➝ $45.00Medium
12/14/2020SVB LeerinkBoost TargetOutperform$45.00 ➝ $50.00High
11/5/2020Needham & Company LLCBoost TargetBuy$44.00 ➝ $47.00Low
10/16/2020Needham & Company LLCReiterated RatingBuy$44.00High
8/12/2020AegisBoost TargetBuy$45.00 ➝ $47.00Low
8/5/2020SVB LeerinkBoost TargetOutperform$40.00 ➝ $45.00Medium
7/22/2020Northland SecuritiesInitiated CoverageOutperform$40.00Medium
7/17/2020BarclaysInitiated CoverageOverweight$45.00High
6/19/2020AegisInitiated CoverageBuy$45.00Medium
6/11/2020Needham & Company LLCUpgradeHold ➝ Buy$44.00High
5/6/2020Needham & Company LLCReiterated RatingHoldHigh
5/6/2020Lake Street CapitalLower TargetBuy$54.00 ➝ $48.00High
4/28/2020SVB LeerinkLower TargetOutperform$60.00 ➝ $50.00High
4/19/2020OppenheimerInitiated CoverageOutperform$47.00Low
4/6/2020OppenheimerInitiated CoverageOutperform$47.00Low
4/3/2020Lake Street CapitalLower TargetBuy$60.00 ➝ $54.00High
10/17/2019GuggenheimInitiated CoverageBuy$58.00High
8/7/2019Needham & Company LLCReiterated RatingHoldLow
8/7/2019Lake Street CapitalBoost TargetBuy$50.00 ➝ $60.00High
7/16/2019Stifel NicolausDowngradeBuy ➝ Hold$41.00 ➝ $45.00Low
5/2/2019Needham & Company LLCReiterated RatingHoldHigh
4/11/2019Bank of AmericaDowngradeBuy ➝ Underperform$42.00High
10/31/2018Needham & Company LLCReiterated RatingHoldHigh
8/22/2018Stifel NicolausInitiated CoverageBuy$45.00Medium
8/1/2018Lake Street CapitalReiterated RatingBuy$50.00Medium
6/27/2018Bank of AmericaUpgradeUnderperform ➝ BuyHigh
5/3/2018Needham & Company LLCReiterated RatingHoldHigh
2/8/2018SVB LeerinkLower TargetOutperform ➝ Outperform$31.00 ➝ $30.00High
12/21/2017William BlairReiterated RatingMarket PerformLow
12/15/2017Needham & Company LLCDowngradeBuy ➝ Hold$33.11 ➝ $23.00High
(Data available from 12/10/2017 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/13/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/12/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/11/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/10/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/9/2022

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Cardiovascular Systems logo
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
Read More

Today's Range

Now: $13.44
Low: $13.29
High: $13.63

50 Day Range

MA: $13.95
Low: $12.74
High: $15.12

52 Week Range

Now: $13.44
Low: $12.26
High: $23.47

Volume

231,027 shs

Average Volume

328,810 shs

Market Capitalization

$562.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardiovascular Systems?

The following equities research analysts have issued reports on Cardiovascular Systems in the last year: Bank of America Co., StockNews.com, and SVB Leerink LLC.
View the latest analyst ratings for CSII.

What is the current price target for Cardiovascular Systems?

1 Wall Street analysts have set twelve-month price targets for Cardiovascular Systems in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 48.8%. SVB Leerink LLC has the highest price target set, predicting CSII will reach $20.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $20.00 for Cardiovascular Systems in the next year.
View the latest price targets for CSII.

What is the current consensus analyst rating for Cardiovascular Systems?

Cardiovascular Systems currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CSII, but not buy more shares or sell existing shares.
View the latest ratings for CSII.

What other companies compete with Cardiovascular Systems?

Other companies that are similar to Cardiovascular Systems include Surmodics, AngioDynamics, Orthofix Medical, Accuray and Alphatec. Learn More about companies similar to Cardiovascular Systems.

How do I contact Cardiovascular Systems' investor relations team?

Cardiovascular Systems' physical mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company's listed phone number is (651) 259-1600 and its investor relations email address is [email protected] The official website for Cardiovascular Systems is www.csi360.com. Learn More about contacing Cardiovascular Systems investor relations.